SCHEMBL3013286

SCHEMBL3013286

COc1ccc(S(=O)(=O)C2CCN(c3nc(Cc4c(C)cc(C)cc4C)cs3)CC2)cc1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
HTT P42858 2/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
RAB9A P51151 3/20 0.37
NPC1 O15118 2/20 0.37
MAPT P10636 1/20 0.37
DNM1L O00429 1/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
AVPR1B P47901 1/20 0.35
TP53 P04637 1/20 0.35
F2RL3 Q96RI0 3/20 0.34
HSD11B1 P28845 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC1 Q13547 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3127546 0.93 HTT (0.44) KDM4ESMN1; SMN2HTTLMNAPOLB
SCHEMBL3012800 0.90 KDM4E (0.40) KDM4ESMN1; SMN2HTTLMNAPOLB
SCHEMBL3002775 0.88 KDM4E (0.40) KDM4ESMN1; SMN2HTTLMNAPOLB
SCHEMBL3015515 0.88 GBA1 (0.42) SMN1; SMN2HTTPOLBRAB9ANPC1
SCHEMBL3017317 0.88 SMN1; SMN2 (0.39) KDM4ESMN1; SMN2HTTLMNAPOLB
SCHEMBL3014450 0.87 KDM4E (0.41) KDM4ESMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3018931 0.87 KDM4E (0.39) KDM4ESMN1; SMN2HTTLMNAPOLB
SCHEMBL3003521 0.87 TSHR (0.41) KDM4ESMN1; SMN2HTTLMNAPOLB
SCHEMBL3005141 0.86 HTT (0.39) KDM4ESMN1; SMN2HTTLMNAPOLB
SCHEMBL3006747 0.86 L3MBTL1 (0.46) SMN1; SMN2HTTLMNARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KDM4E 4398/4885SMN1; SMN2 1/4885HTT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.